Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease

Página do item simplificado
dc.citation.issue2
dc.citation.volumev. 196
dc.contributor.authorFaria-Urbina, Mariana
dc.contributor.authorOliveira, Rudolf Krawczenko Feitoza de [UNIFESP]
dc.contributor.authorAgarwal, Manyoo
dc.contributor.authorWaxman, Aaron B.
dc.coverageNew York
dc.date.accessioned2020-07-20T16:31:12Z
dc.date.available2020-07-20T16:31:12Z
dc.date.issued2018
dc.description.abstractPulmonary hypertension (PH) in the setting of parenchymal lung disease adversely affects quality of life and survival. However, PH-specific drugs may result in ventilation/perfusion imbalance and currently, there are no approved PH treatments for this patient population. In the present retrospective study, data from 22 patients with PH associated with lung disease treated with inhaled treprostinil (iTre) and followed up clinically for at least 3 months are presented. PH was defined by resting right heart catheterization as a mean pulmonary artery pressure (mPAP) >= 35 mmHg, or mPAP >= 25 mmHg associated with pulmonary vascular resistance >= 4 Woods Units. Follow-up evaluation was performed at the discretion of the attending physician. From baseline to follow-up, we observed significant improvement in functional class (n = 22, functional class III-IV 82 vs. 59%, p = 0.041) and 6-min walk distance (n = 11, 243 +/- 106 vs. 308 +/- 109en
dc.description.abstractp = 0.022), without a deleterious effect on resting peripheral oxygen saturation (n = 22, 92 +/- 6 vs. 94 +/- 4en
dc.description.abstractp = 0.014). Most of the patients (86%, n = 19/22) were using long-term nasal supplemental oxygen at baseline. During follow-up, only one patient had increased supplemental oxygen requirement. The most common adverse events were cough, headache, and diarrhea. No severe adverse event was reported. The results suggest that iTre is safe in patients with Group 3 PH and evidence of pulmonary vascular remodeling in terms of functional class, gas exchange, and exercise capacity. Additionally, iTre was well tolerated. The potential role of PH-specific drugs in Group 3 PH should be further assessed in larger prospective studies.en
dc.description.affiliationBrigham & Womens Hosp, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA
dc.description.affiliationHarvard Med Sch, Boston, MA 02115 USA
dc.description.affiliationBrigham & Womens Hosp, Ctr Pulm Heart Dis, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Div Resp Dis, Dept Med, Sao Paulo, Brazil
dc.description.affiliationUniv Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA
dc.description.affiliationBrigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St,PBB Clin 3, Boston, MA 02115 USA
dc.description.affiliationUnifespFed Univ Sao Paulo UNIFESP, Div Resp Dis, Dept Med, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP)
dc.description.sponsorshipBrazilian National Council for Scientific and Technological Development (CNPq)
dc.description.sponsorshipNIH
dc.description.sponsorshipIDFAPESP: 2014/12212-5
dc.description.sponsorshipIDCNPq: 232643/2014-8
dc.description.sponsorshipIDNIH: U01HL125215
dc.format.extent139-146
dc.identifierhttp://dx.doi.org/10.1007/s00408-017-0081-7
dc.identifier.citationLung. New York, v. 196, n. 2, p. 139-146, 2018.
dc.identifier.doi10.1007/s00408-017-0081-7
dc.identifier.issn0341-2040
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55783
dc.identifier.wosWOS:000427629200002
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofLung
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectPulmonary hypertensionen
dc.subjectLung diseaseen
dc.subjectTreprostinilen
dc.subjectExercise capacityen
dc.titleInhaled Treprostinil in Pulmonary Hypertension Associated with Lung Diseaseen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos